Recently, in one of the most extensive studies with ctDNA on 8388 advanced NSCLC patients, activating alterations in actionable oncogenes were identified in 48% of patients, including EGFR (26.4%), MET (6.1%), and BRAF (2.8%) alterations and fusions (ALK, RET, and ROS1) in 2.3% [121]. Here, ROS1 is linked to non-small cell lung carcinoma.